ru24.pro
News in English
Январь
2025

Trastuzumab emtansine improves long-term survival in HER2 breast cancer

0
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase 3 KATHERINE clinical trial.